Activity of EGFR TKIs in Caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations
A Passaro, A Prelaj, L Bonanno, M Tiseo, A Tuzi… - Clinical lung cancer, 2019 - Elsevier
Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …
predictive and druggable mutations that greatly modified patient prognoses. The most …
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence
Compound epidermal growth factor receptor (EGFR) mutations represent a heterogeneous
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …
subgroup of non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations …
Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG)
Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and …
I Sullivan, D Planchard - Therapeutic advances in respiratory …, 2016 - journals.sagepub.com
Patients with advanced epidermal growth factor receptor (EGFR) mutant non-small cell lung
cancer (NSCLC) are particularly sensitive to treatment with first-or second-generation EGFR …
cancer (NSCLC) are particularly sensitive to treatment with first-or second-generation EGFR …
Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): the road to a success, paved with failures
DH Lee - Pharmacology & therapeutics, 2017 - Elsevier
The discovery of epidermal growth factor receptor (EGFR) activating mutations in non-small
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
cell lung cancer (NSCLC) and the success story of EGFR tyrosine kinases inhibitors (TKIs) …
Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
B Melosky - Frontiers in oncology, 2014 - frontiersin.org
Recent clinical trials have demonstrated the efficacy of epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic …
(EGFR) tyrosine kinase inhibitors (TKI) in the treatment of patients with advanced metastatic …
[HTML][HTML] Meta-analysis of first-line therapies in advanced non–small-cell lung cancer harboring EGFR-activating mutations
Introduction: Tyrosine kinase inhibitors gefitinib, erlotinib, and afatinib have been compared
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
with chemotherapy as first-line therapies for patients with advanced non–small-cell lung …
[HTML][HTML] Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop
R Pirker, FJF Herth, KM Kerr, M Filipits, M Taron… - Journal of Thoracic …, 2010 - Elsevier
Introduction: Activating somatic mutations of the tyrosine kinase domain of epidermal growth
factor receptor (EGFR) have recently been characterized in a subset of patients with …
factor receptor (EGFR) have recently been characterized in a subset of patients with …
[HTML][HTML] Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI …
Y Sakata, S Sakata, Y Oya, M Tamiya, H Suzuki… - European Journal of …, 2021 - Elsevier
Background Osimertinib is the standard of care in the initial treatment for advanced
epidermal growth factor receptor (EGFR) mutation–positive lung cancer. However, clinical …
epidermal growth factor receptor (EGFR) mutation–positive lung cancer. However, clinical …
Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib
Y Liu, Y Li, Q Ou, X Wu, X Wang, YW Shao, J Ying - Lung Cancer, 2018 - Elsevier
Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
promising targeted therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) …
promising targeted therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) …